Cipla remains top deafulter in NPPA list

The National Pharmaceutical Pricing Authority's (NPPA) record of recovering extra amounts charged by pharmaceutical companies, over and above the government-fixed maximum retail price of select drugs, continues to be abysmal. Thanks to an it has with drug major Ltd.

About 65 per cent (Rs 1,555 crore) of the total overcharged amount of Rs 2,357 crore, demanded by from drug so far, has to be recovered from alone. The amount includes the unpaid amount and interest component added up to July 31.

The figures are higher than Rs 1,230.28 crore, the amount disclosed by as the aggregate demand (inclusive of interest) sought by the medicine price regulator from the company. This is part of the company's quarterly disclosures to the stock exchanges, and is based on the demand notices issued by for the July 1995 – April 2009 period.

had stated that it has been contesting the demand notices issued by since 2003 in various courts. The matter had reached the Supreme Court from where it was re-directed to the Bombay High Court for interpreting the on the basis of the directions and principles laid down by the court. It had also restrained the government from taking coercive action against Cipla.

There are 15 separate demand notices issued by against for alleged overcharging of drugs such as Ciprofloxacin, Salbutamol, and Norfloxacin.

Most of the leading firms such as Pfizer, Cadila, Dr Reddys’, etc also figure in the list of that were served notices for recovering overcharged amounts.

has so far issued 812 price recovery notices to over 200 drug firms during the last 14 years. In nearly 600 cases, the have complied with the directives and cleared their dues. The agency recovered Rs 211 crore till July 31.

image
Business Standard
177 22
Business Standard

Cipla remains top deafulter in NPPA list

Joe C Mathew  |  New Delhi 



The National Pharmaceutical Pricing Authority's (NPPA) record of recovering extra amounts charged by pharmaceutical companies, over and above the government-fixed maximum retail price of select drugs, continues to be abysmal. Thanks to an it has with drug major Ltd.

About 65 per cent (Rs 1,555 crore) of the total overcharged amount of Rs 2,357 crore, demanded by from drug so far, has to be recovered from alone. The amount includes the unpaid amount and interest component added up to July 31.

The figures are higher than Rs 1,230.28 crore, the amount disclosed by as the aggregate demand (inclusive of interest) sought by the medicine price regulator from the company. This is part of the company's quarterly disclosures to the stock exchanges, and is based on the demand notices issued by for the July 1995 – April 2009 period.

had stated that it has been contesting the demand notices issued by since 2003 in various courts. The matter had reached the Supreme Court from where it was re-directed to the Bombay High Court for interpreting the on the basis of the directions and principles laid down by the court. It had also restrained the government from taking coercive action against Cipla.

There are 15 separate demand notices issued by against for alleged overcharging of drugs such as Ciprofloxacin, Salbutamol, and Norfloxacin.

Most of the leading firms such as Pfizer, Cadila, Dr Reddys’, etc also figure in the list of that were served notices for recovering overcharged amounts.

has so far issued 812 price recovery notices to over 200 drug firms during the last 14 years. In nearly 600 cases, the have complied with the directives and cleared their dues. The agency recovered Rs 211 crore till July 31.

RECOMMENDED FOR YOU

Cipla remains top deafulter in NPPA list

The National Pharmaceutical Pricing Authority's (NPPA) record of recovering extra amounts charged by pharmaceutical companies, over and above the government-fixed maximum retail price of select drugs, continues to be abysmal. Thanks to an eight-year-old litigation it has with drug major Cipla Ltd.

The National Pharmaceutical Pricing Authority's (NPPA) record of recovering extra amounts charged by pharmaceutical companies, over and above the government-fixed maximum retail price of select drugs, continues to be abysmal. Thanks to an it has with drug major Ltd.

About 65 per cent (Rs 1,555 crore) of the total overcharged amount of Rs 2,357 crore, demanded by from drug so far, has to be recovered from alone. The amount includes the unpaid amount and interest component added up to July 31.

The figures are higher than Rs 1,230.28 crore, the amount disclosed by as the aggregate demand (inclusive of interest) sought by the medicine price regulator from the company. This is part of the company's quarterly disclosures to the stock exchanges, and is based on the demand notices issued by for the July 1995 – April 2009 period.

had stated that it has been contesting the demand notices issued by since 2003 in various courts. The matter had reached the Supreme Court from where it was re-directed to the Bombay High Court for interpreting the on the basis of the directions and principles laid down by the court. It had also restrained the government from taking coercive action against Cipla.

There are 15 separate demand notices issued by against for alleged overcharging of drugs such as Ciprofloxacin, Salbutamol, and Norfloxacin.

Most of the leading firms such as Pfizer, Cadila, Dr Reddys’, etc also figure in the list of that were served notices for recovering overcharged amounts.

has so far issued 812 price recovery notices to over 200 drug firms during the last 14 years. In nearly 600 cases, the have complied with the directives and cleared their dues. The agency recovered Rs 211 crore till July 31.

image
Business Standard
177 22
Widgets Magazine

More News

  • Premier Futsal to spend Rs 45 crore on marketing in debut year Premier Futsal to go global in season-2
  • Canada Pension Plan hikes stake in Kotak Mahindra Bank CPPIB gets RBI nod to hike stake in Kotak Mahindra Bank
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard